SP-002, Vismodegib — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of
Phase 2 · Basal Cell Carcinoma |
Stamford Pharmaceuticals, Inc. | SP-002, Vismodegib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|